Shares of Clover Health Corp. (NASDAQ: CLOV) surged by nearly 6% on Thursday, propelled by positive developments related to its Medicare Advantage plans and benchmark rates from the Centers for Medicare & Medicaid Services (CMS).
For the 2025 plan year, CMS awarded Clover Health's Medicare Advantage PPO plans a coveted 4-star quality rating, while its HMO plans received a respectable 3.5-star rating. These high ratings are expected to significantly boost Clover Health's competitiveness and ability to attract and retain Medicare Advantage enrollees, a key driver of growth for the company.
Furthermore, Clover Health announced that its 4-star rating for its PPO contract will lead to a general 5% increase in benchmark payment rates for the 2026 plan year. This increase in benchmark rates, which are used to determine Medicare Advantage plan reimbursements from CMS, is expected to directly translate into higher revenues for the company.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。